The overall majority (87%) of our CVID patients failed to produce IgA antibodies against SARS-CoV-2 spike protein, including even patients who were capable of producing IgG antibodies following BNT162b2 vaccination. This evidence concerns the gene CD79A and common variable immunodeficiency.